Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 2, 2010, Pages 147-155

  Azzarello, Joseph T ^a   Lin, Hsueh Kung ^a,b   Gherezghiher, Awet ^a   Zakharov, Vladislav ^a   Yu, Zhongxin ^a   Kropp, Bradley P ^a   Culkin, Daniel J ^a   Penning, Trevor M ^c   Fung, Kar Ming ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aldo keto reductase; Kidney cancer; Papillary urothelial carcinoma; Renal cell carcinoma; Wilms' tumor

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHILD; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; NEPHROBLASTOMA; PATHOLOGY; PRESCHOOL CHILD; TRANSITIONAL CELL CARCINOMA;

3-HYDROXYSTEROID DEHYDROGENASES; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; INFANT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; WILMS TUMOR;

EID: 77951638901     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jez JM, Flynn TG and Penning TM. A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 1997; 54: 639-647.
2. Jez JM, Bennett MJ, Schlegel BP, Lewis M and Penning TM. Comparative anatomy of the aldoketo reductase superfamily. Biochem J 1997; 326 (Pt 3): 625-636.
3. Hyndman D, Bauman DR, Heredia VV and Penning TM. The aldo-keto reductase superfamily homepage. Chem Biol Interact 2003; 143-144: 621-631.
4. Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y and Ishida N. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J 1996; 313: 373-376.
5. Dufort I, Soucy P, Labrie F and Luu-The V. Molecular cloning of human type 3 3a-hydroxysteroid dehydrogenase that differs from 20a-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophy Res Communication 1996; 228: 474-479.
6. Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K and Hara A. Molecular cloning of two human liver 3a-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J 1994; 299: 545-552.
7. Khanna M, Qin KN, Wang RW and Cheng KC. Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3a-hydroxysteroid dehydrogenases. J Biol Chem 1995; 270: 20162-20168.
8. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA and Penning TM. Expression and characterization of recombinant type 2 3a-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3a/17b-HSD activity and cellular distribution. Mol Endocrinol 1997; 11: 1971-1984.
9. Dufort I, Rheault P, Huang XF, Soucy P and Luu-The V. Characteristics of a highly labile human type 5 17b-hydroxysteroid dehydrogenase. Endocrinology 1999; 140: 568-574.
10. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N and Ratnam K. Human 3a-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000; 351: 67-77.
11. Matsuura K, Shiraishi H, Hara A, Sato K, Deyashiki Y, Ninomiya M and Sakai S. Identification of a principal mRNA species for human 3a-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem (Tokyo) 1998; 124: 940-946.
12. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl DM, Fung KM and Lin HK. Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006; 248: 182-191.
13. Mahadevan D, DiMento J, Croce KD, Riley C, George B, Fuchs D, Mathews T, Wilson C and Lobell M. Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia. Am J Hematol 2006; 81: 779-786.
14. Lewis MJ, Wiebe JP and Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004; 4: 27.
15. Rizner TL, Smuc T, Rupreht R, Sinkovec J and Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006; 248: 126-135.
16. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, He X, Yeager M, Welch R, Chanock S, Tian L, Chapman RS, Zheng T, Keohavong P, Caporaso N and Rothman N. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 2004; 25: 2177-2181.
17. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y and Sasano H. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005; 12: 101-107.
18. Fung KM, Samara ENS, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JT, Culkin DJ, Kropp BP, Penning TM and Lin HK. Increased expression of type 2 3ahydroxysteroid dehydrogenase/type 5 17bhydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006; 13: 169-180.
19. Stanbrough M, Bubley G, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG and Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
20. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T and Naito M. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008; 61: 448-454.
21. Eble JN, Togashi K and Pisani P. Renal cell carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn I, editors. World Health Organization Classification of Tumours. Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004. p. 12-14.
22. Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP and Menck HR. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997; 80: 2321-2332.
23. Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Scmitz-Drager BJ, Helpap B, Ayala AG and Tamboli P. Infiltrating urothelial carcinoma In: Eble JN, Sauter G, Epstein JI, Sesterhenn I, editors. World Health Organization Classification of Tumours. Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004. p. 93-109.
24. Azzarello J, Fung KM and Lin HK. Tissue distribution of human AKR1C3 and rat homolog in adult genitourinary system. J Histochem Cytochem 2008; 56: 853-861.
25. Lin HK, Steckelbroeck S, Fung KM, Jones AN and Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3a-hydroxysteroid dehydrogenase/type 5 17b-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004; 69: 795-801.
26. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F and Pelletier G. Localization of type 5 17bhydroxysteroid dehydrogenase, 3ahydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinol 1999; 140: 1481-1491.
27. Quinkler M, Bumke-Vogt C, Meyer B, Bahr V, Oelkers W and Diederich S. The human kidney is a progesterone-metabolizing and androgenproducing organ. J Clin Endocrinol Metab 2003; 88: 2803-2809.
28. Hao CM and Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008; 70: 357-377.
29. Condon J, Gosden C, Gardener D, Nickson P, Hewison M, Howie AJ and Stewart PM. Expression of type 2 11beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. J Clin Endocrinol Metab 1998; 83: 4490-4497.
30. Abdelgadir SE, Connolly PB and Resko JA. Androgen binding in peripheral tissues of fetal rhesus macaques: effects of androgen metabolism in liver. J Steroid Biochem Mol Biol 1990; 37: 545-551.
31. Gleason CA. Prostaglandins and the developing kidney. Semin Perinatol 1987; 11: 12-21.
32. van der Heijden BJ, Carlus C, Narcy F, Bavoux F, Delezoide AL and Gubler MC. Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin. Am J Obstet Gynecol 1994; 171: 617-623.
33. Komhoff M, Wang JL, Cheng HF, Langenbach R, McKanna JA, Harris RC and Breyer MD. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000; 57: 414-422.
34. Sharma KK, Lindqvist A, Zhou XJ, Auchus RJ, Penning TM and Andersson S. Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues. Mol Cell Endocrinol 2006; 248: 79-86.
35. Inoue T, Akahira JI, Takeyama J, Suzuki T, Darnel AD, Kaneko C, Kurokawa Y, Satomi S and Sasano H. Spatial and topological distribution of progesterone receptor A and B isoforms during human development. Mol Cell Endocrinol 2001; 182: 83-89.
36. Dalla Valle L, Toffolo V, Vianello S, Belvedere P and Colombo L. Expression of cytochrome P450c17 and other steroid-converting enzymes in the rat kidney throughout the lifespan. J Steroid Biochem Mol Biol 2004; 91: 49-58.
37. Nakagawa M, Tsukada F, Nakayama T, Matsuura K, Hara A and Sawada H. Identification of two dihydrodiol dehydrogenases associated with 3(17)a-hydroxysteroid dehydrogenase activity in mouse kidney. J Biochem 1989; 106: 633-638.